Research
Hormonal
Tirzepatide (a dual GIP/GLP-1 agonist) is better tolerated regarding GI side effects compared to semaglutide (a GLP-1 agonist), likely due to GIP receptor activation having anti-emetic properties.
If you struggle with stomach issues on Semaglutide (Ozempic/Wegovy), ask your doctor about Tirzepatide (Mounjaro/Zepbound). Clinical trials show it causes fewer GI side effects and fewer people stop taking it, possibly because of how it interacts with GIP receptors in the gut.
GoodSupportsHIGH confidence
Tirzepatide appears to be better tolerated than semaglutide, which may relate to its dual GLP-1R and GIP receptor (GIPR) action... emerging data suggest that GIPR activation may have anti-emetic properties, which could mitigate GI AEs occurrence
Why this rating
Based on head-to-head trials (SURMOUNT-5) and mechanistic studies cited.
Source
Gastrointestinal Symptoms in Obesity Therapy: Mechanisms, Epidemiology, and Management Strategies
Tomasz Witaszek et al. · Biomedicines · 2025
DOI 10.3390/biomedicines13102362
narrative_reviewCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Incretin-based anti-obesity medications (GLP-1 and GIP/GLP-1 receptor agonists) cause gastrointestinal adverse effects (nausea, diarrhea, constipation) in 65–84% of patients, primarily through delayed gastric emptying and central appetite signaling activation.Good
- Rapid weight loss, whether from very-low-calorie diets or bariatric surgery, significantly increases the risk of gallstone formation (cholelithiasis) due to bile supersaturation and reduced gallbladder motility.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →